Lorus Toxicology Program Supports Novel Route of Administration of the Anticancer Drug LOR-2040 in Bladder Cancer
Lorus Therapeutics Inc. (TSX:LOR)(AMEX:LRP) (\"Lorus\"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the successful completion of GLP toxicology studies to explore a novel route of administration for its clinical-stage anticancer drug, LOR-2040.
Two studies were conducted to assess toxicity of LOR-2040 when administered by intravesical (direct) administration into the bladder. In both studies, no evidence of toxicity was seen following single or repeated doses of LOR-2040 given with this method of administration. Toxicity was evaluated based on a wide range of observations including detailed examination of urinary tract tissues.
- Published: 05 August 2008
- Written by Editor